1
|
Li Y, Huang X, Fowler C, Lim YY, Laws SM, Faux N, Doecke JD, Trounson B, Pertile K, Rumble R, Doré V, Villemagne VL, Rowe CC, Wiley JS, Maruff P, Masters CL, Gu BJ. Identification of Leukocyte Surface P2X7 as a Biomarker Associated with Alzheimer's Disease. Int J Mol Sci 2022; 23:ijms23147867. [PMID: 35887215 PMCID: PMC9322488 DOI: 10.3390/ijms23147867] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/17/2022] [Revised: 07/10/2022] [Accepted: 07/12/2022] [Indexed: 02/04/2023] Open
Abstract
Alzheimer's disease (AD) has shown altered immune responses in the periphery. We studied P2X7 (a proinflammatory receptor and a scavenger receptor) and two integrins, CD11b and CD11c, on the surface of circulating leukocytes and analysed their associations with Aβ-PET, brain atrophy, neuropsychological assessments, and cerebrospinal fluid (CSF) biomarkers. Total 287 age-matched, sex-balanced participants were recruited in a discovery cohort and two validation cohorts through the AIBL study and studied using tri-colour flow cytometry. Our results demonstrated reduced expressions of P2X7, CD11b, and CD11c on leukocytes, particularly monocytes, in Aβ +ve cases compared with Aβ -ve controls. P2X7 and integrin downregulation was observed at pre-clinical stage of AD and stayed low throughout disease course. We further constructed a polygenic risk score (PRS) model based on 12 P2RX7 risk alleles to assess the genetic impact on P2X7 function in AIBL and ADNI cohorts. No significant association was identified between the P2RX7 gene and AD, indicating that P2X7 downregulation in AD is likely caused by environmental changes rather than genetic factors. In conclusion, the downregulation of P2X7 and integrins at pre-clinical stage of AD indicates altered pro-inflammatory responses, phagocytic functions, and migrating capabilities of circulating monocytes in early AD pathogenesis. Our study not only improves our understanding of peripheral immune involvement in early stage of AD but also provides more insights into novel biomarker development, diagnosis, and prognosis of AD.
Collapse
Affiliation(s)
- Yihan Li
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Xin Huang
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Christopher Fowler
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Yen Y. Lim
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia; (Y.Y.L.); (V.D.)
| | - Simon M. Laws
- School of Medical and Health Sciences, Edith Cowan University, 270 Joondalup Drive, Joondalup, WA 6027, Australia;
| | - Noel Faux
- Melbourne Data Analytics Platform, Petascale Campus Initiative, The University of Melbourne, 21 Bedford St., North Melbourne, VIC 3051, Australia;
| | - James D. Doecke
- The Australian e-Health Research Centre, CSIRO, Brisbane, QLD 4029, Australia;
| | - Brett Trounson
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Kelly Pertile
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Rebecca Rumble
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Vincent Doré
- School of Psychological Sciences, Turner Institute for Brain and Mental Health, Monash University, Clayton, VIC 3168, Australia; (Y.Y.L.); (V.D.)
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
| | - Victor L. Villemagne
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
- Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - Christopher C. Rowe
- Department of Molecular Imaging & Therapy, Austin Health, Melbourne, VIC 3084, Australia; (V.L.V.); (C.C.R.)
- Department of Medicine, The University of Melbourne, Melbourne, VIC 3084, Australia
| | - James S. Wiley
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
- CogState Ltd., Melbourne, VIC 3001, Australia
| | - Colin L. Masters
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
| | - Ben J. Gu
- The Florey Institute, The University of Melbourne, 30 Royal Parade, Parkville, VIC 3052, Australia; (Y.L.); (X.H.); (C.F.); (B.T.); (K.P.); (R.R.); (J.S.W.); (P.M.); (C.L.M.)
- National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai 200040, China
- Correspondence: ; Tel.: +61-3-9035-6317
| |
Collapse
|
2
|
Cacciamani F, Godefroy V, Brambati SM, Migliaccio R, Epelbaum S, Montembeault M. Differential Patterns of Domain-Specific Cognitive Complaints and Awareness Across the Alzheimer's Disease Spectrum. Front Aging Neurosci 2022; 14:811739. [PMID: 35813963 PMCID: PMC9261482 DOI: 10.3389/fnagi.2022.811739] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/09/2021] [Accepted: 04/29/2022] [Indexed: 11/26/2022] Open
Abstract
Background: Characterizing self- and informant-reported cognitive complaints, as well as awareness of cognitive decline (ACD), is useful for an early diagnosis of Alzheimer's disease (AD). However, complaints and ACD related to cognitive functions other than memory are poorly studied. Furthermore, it remains unclear which source of information is the most useful to distinguish various groups on the AD spectrum. Methods: Self- and informant-reported complaints were measured with the Everyday Cognition questionnaire (ECog-Subject and ECog-StudyPartner) in four domains (memory, language, visuospatial, and executive). ACD was measured as the subject-informant discrepancy in the four ECog scores. We compared the ECog and ACD scores across cognitive domains between four groups: 71 amyloid-positive individuals with amnestic AD, 191 amnestic mild cognitive impairment (MCI), or 118 cognitively normal (CN), and 211 amyloid-negative CN controls, selected from the ADNI database. Receiver operating characteristic curves analysis was performed to evaluate the accuracy of the ECog and ACD scores in discriminating clinical groups. Results: Self- and informant-reported complaints were generally distributed as follows: memory, language, executive, and visuospatial (from the most severe to the least severe). Both groups of CN participants presented on average more memory and language complaints than their informant. MCI participants showed good agreement with their informants. AD participants presented anosognosia in all domains, but especially for the executive domain. The four ECog-StudyPartner sub-scores allowed excellent discrimination between groups in almost all classifications and performed significantly better than the other two classifiers considered. The ACD was excellent in distinguishing the participants with AD from the two groups of CN participants. The ECog-Subject was the least accurate in discriminating groups in four of the six classifications performed. Conclusion: In research, the study of complaint and anosognosia should not be reduced solely to the memory domain. In clinical practice, non-amnestic complaints could also be linked to Alzheimer's disease. The presence of an informant also seems necessary given its accuracy as a source of information.
Collapse
Affiliation(s)
- Federica Cacciamani
- ARAMISLab, Inserm, CNRS, Sorbonne Université, Inria, Paris Brain Institute (ICM), Pitié-Salpêtrière Hospital, Paris, France
- PHARes Team, Bordeaux Population Health, University of Bordeaux, Inserm, Bordeaux, France
| | - Valérie Godefroy
- FrontLab, Paris Brain Institute (ICM), Pitié-Salpêtrière Hospital, Paris, France
| | - Simona M. Brambati
- Department of Psychology, University of Montreal, Montreal, QC, Canada
- Centre de recherche de l’Institut Universitaire de Gériatrie de Montréal, Montréal, QC, Canada
| | - Raffaella Migliaccio
- FrontLab, Paris Brain Institute (ICM), Pitié-Salpêtrière Hospital, Paris, France
- Institute of Memory and Alzheimer’s disease (IM2A), Pitié-Salpêtrière Hospital, Paris, France
| | - Stéphane Epelbaum
- ARAMISLab, Inserm, CNRS, Sorbonne Université, Inria, Paris Brain Institute (ICM), Pitié-Salpêtrière Hospital, Paris, France
- Institute of Memory and Alzheimer’s disease (IM2A), Pitié-Salpêtrière Hospital, Paris, France
| | - Maxime Montembeault
- Douglas Mental Health University Institute, Montreal, QC, Canada
- Department of Psychiatry, McGill University, Montreal, QC, Canada
- Memory & Aging Center, Department of Neurology, University of California, San Francisco, San Francisco, CA, United States
| |
Collapse
|
3
|
Shishegar R, Cox T, Rolls D, Bourgeat P, Doré V, Lamb F, Robertson J, Laws SM, Porter T, Fripp J, Tosun D, Maruff P, Savage G, Rowe CC, Masters CL, Weiner MW, Villemagne VL, Burnham SC. Using imputation to provide harmonized longitudinal measures of cognition across AIBL and ADNI. Sci Rep 2021; 11:23788. [PMID: 34893624 PMCID: PMC8664816 DOI: 10.1038/s41598-021-02827-6] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2021] [Accepted: 11/12/2021] [Indexed: 12/12/2022] Open
Abstract
To improve understanding of Alzheimer’s disease, large observational studies are needed to increase power for more nuanced analyses. Combining data across existing observational studies represents one solution. However, the disparity of such datasets makes this a non-trivial task. Here, a machine learning approach was applied to impute longitudinal neuropsychological test scores across two observational studies, namely the Australian Imaging, Biomarkers and Lifestyle Study (AIBL) and the Alzheimer's Disease Neuroimaging Initiative (ADNI) providing an overall harmonised dataset. MissForest, a machine learning algorithm, capitalises on the underlying structure and relationships of data to impute test scores not measured in one study aligning it to the other study. Results demonstrated that simulated missing values from one dataset could be accurately imputed, and that imputation of actual missing data in one dataset showed comparable discrimination (p < 0.001) for clinical classification to measured data in the other dataset. Further, the increased power of the overall harmonised dataset was demonstrated by observing a significant association between CVLT-II test scores (imputed for ADNI) with PET Amyloid-β in MCI APOE-ε4 homozygotes in the imputed data (N = 65) but not for the original AIBL dataset (N = 11). These results suggest that MissForest can provide a practical solution for data harmonization using imputation across studies to improve power for more nuanced analyses.
Collapse
Affiliation(s)
- Rosita Shishegar
- The Australian e-Health Research Centre, CSIRO, Melbourne, Australia. .,School of Psychological Sciences and Turner Institute for Brain and Mental Health, Monash University, Melbourne, Australia.
| | - Timothy Cox
- The Australian e-Health Research Centre, CSIRO, Melbourne, Australia
| | - David Rolls
- The Australian e-Health Research Centre, CSIRO, Melbourne, Australia
| | - Pierrick Bourgeat
- The Australian e-Health Research Centre, CSIRO, Melbourne, Australia
| | - Vincent Doré
- The Australian e-Health Research Centre, CSIRO, Melbourne, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Fiona Lamb
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Joanne Robertson
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Simon M Laws
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Tenielle Porter
- Centre for Precision Health, Edith Cowan University, Joondalup, WA, Australia.,Collaborative Genomics and Translation Group, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Jurgen Fripp
- The Australian e-Health Research Centre, CSIRO, Melbourne, Australia
| | - Duygu Tosun
- Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, USA
| | | | - Greg Savage
- Department of Psychology, Macquarie University, Sydney, NSW, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,Department of Medicine, The University of Melbourne, Parkville, VIC, 3052, Australia
| | - Colin L Masters
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Michael W Weiner
- Department of Radiology and Biomedical Imaging, University of California-San Francisco, San Francisco, CA, USA
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
| | | |
Collapse
|
4
|
Fowler C, Rainey-Smith SR, Bird S, Bomke J, Bourgeat P, Brown BM, Burnham SC, Bush AI, Chadunow C, Collins S, Doecke J, Doré V, Ellis KA, Evered L, Fazlollahi A, Fripp J, Gardener SL, Gibson S, Grenfell R, Harrison E, Head R, Jin L, Kamer A, Lamb F, Lautenschlager NT, Laws SM, Li QX, Lim L, Lim YY, Louey A, Macaulay SL, Mackintosh L, Martins RN, Maruff P, Masters CL, McBride S, Milicic L, Peretti M, Pertile K, Porter T, Radler M, Rembach A, Robertson J, Rodrigues M, Rowe CC, Rumble R, Salvado O, Savage G, Silbert B, Soh M, Sohrabi HR, Taddei K, Taddei T, Thai C, Trounson B, Tyrrell R, Vacher M, Varghese S, Villemagne VL, Weinborn M, Woodward M, Xia Y, Ames D. Fifteen Years of the Australian Imaging, Biomarkers and Lifestyle (AIBL) Study: Progress and Observations from 2,359 Older Adults Spanning the Spectrum from Cognitive Normality to Alzheimer's Disease. J Alzheimers Dis Rep 2021; 5:443-468. [PMID: 34368630 PMCID: PMC8293663 DOI: 10.3233/adr-210005] [Citation(s) in RCA: 50] [Impact Index Per Article: 16.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/06/2023] Open
Abstract
Background: The Australian Imaging, Biomarkers and Lifestyle (AIBL) Study commenced in 2006 as a prospective study of 1,112 individuals (768 cognitively normal (CN), 133 with mild cognitive impairment (MCI), and 211 with Alzheimer’s disease dementia (AD)) as an ‘Inception cohort’ who underwent detailed ssessments every 18 months. Over the past decade, an additional 1247 subjects have been added as an ‘Enrichment cohort’ (as of 10 April 2019). Objective: Here we provide an overview of these Inception and Enrichment cohorts of more than 8,500 person-years of investigation. Methods: Participants underwent reassessment every 18 months including comprehensive cognitive testing, neuroimaging (magnetic resonance imaging, MRI; positron emission tomography, PET), biofluid biomarkers and lifestyle evaluations. Results: AIBL has made major contributions to the understanding of the natural history of AD, with cognitive and biological definitions of its three major stages: preclinical, prodromal and clinical. Early deployment of Aβ-amyloid and tau molecular PET imaging and the development of more sensitive and specific blood tests have facilitated the assessment of genetic and environmental factors which affect age at onset and rates of progression. Conclusion: This fifteen-year study provides a large database of highly characterized individuals with longitudinal cognitive, imaging and lifestyle data and biofluid collections, to aid in the development of interventions to delay onset, prevent or treat AD. Harmonization with similar large longitudinal cohort studies is underway to further these aims.
Collapse
Affiliation(s)
- Christopher Fowler
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.,School of Psychological Science, University of Western Australia, Crawley, WA, Australia
| | - Sabine Bird
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Julia Bomke
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Pierrick Bourgeat
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Belinda M Brown
- Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia
| | - Samantha C Burnham
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Ashley I Bush
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Carolyn Chadunow
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Steven Collins
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - James Doecke
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia.,Cooperative Research Council for Mental Health, Melbourne, VIC, Australia
| | - Vincent Doré
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia.,Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Kathryn A Ellis
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.,University of Melbourne Academic Unit for Psychiatry of Old Age, Parkville, VIC, Australia.,Melbourne School of Psychological Sciences, Melbourne, VIC, Australia
| | - Lis Evered
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia
| | - Amir Fazlollahi
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Jurgen Fripp
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Samantha L Gardener
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Simon Gibson
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Robert Grenfell
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Elise Harrison
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Richard Head
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Liang Jin
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Adrian Kamer
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Fiona Lamb
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | | | - Simon M Laws
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Qiao-Xin Li
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Lucy Lim
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Yen Ying Lim
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.,Turner Institute for Brain and Mental Health, School of Psychological Sciences, Monash University, Clayton, VIC, Australia
| | - Andrea Louey
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - S Lance Macaulay
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Lucy Mackintosh
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | | | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Simon McBride
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Lidija Milicic
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Madeline Peretti
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia
| | - Kelly Pertile
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Tenielle Porter
- Collaborative Genomics and Translation Group, Centre for Precision Health, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,School of Pharmacy and Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Bentley, WA, Australia
| | - Morgan Radler
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Alan Rembach
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Joanne Robertson
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Mark Rodrigues
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Rebecca Rumble
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | | | - Greg Savage
- Department of Psychology, Macquarie University, Sydney, NSW, Australia
| | - Brendan Silbert
- Department of Anaesthesia and Acute Pain Medicine, St Vincent's Hospital Melbourne, Victoria Parade, Fitzroy, VIC, Australia
| | - Magdalene Soh
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Hamid R Sohrabi
- Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,Centre for Healthy Ageing, Health Futures Institute, Murdoch University, Murdoch, WA, Australia.,Department of Biomedical Sciences, Macquarie University, North Ryde, NSW, Australia
| | - Kevin Taddei
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Tania Taddei
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia
| | - Christine Thai
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Brett Trounson
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Regan Tyrrell
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia
| | - Michael Vacher
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - Shiji Varghese
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia
| | - Victor L Villemagne
- Department of Molecular Imaging and Therapy, Austin Health, Heidelberg, VIC, Australia.,Department of Psychiatry, University of Pittsburgh, Pittsburgh, PA, USA
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Australian Alzheimer's Research Foundation (Ralph and Patricia Sarich Neuroscience Research Institute), Nedlands, WA, Australia.,School of Psychological Science, University of Western Australia, Crawley, WA, Australia
| | - Michael Woodward
- Department of Geriatric Medicine Austin Hospital, Heidelberg, VIC, Australia
| | - Ying Xia
- Australian E-Health Research Centre, CSIRO Health & Biosecurity, Herston, QLD, Australia
| | - David Ames
- The Florey Institute, The University of Melbourne, Parkville, VIC, Australia.,University of Melbourne Academic Unit for Psychiatry of Old Age, Parkville, VIC, Australia.,National Ageing Research Institute (NARI), Parkville, VIC, Australia
| | | |
Collapse
|
5
|
Sutoko S, Masuda A, Kandori A, Sasaguri H, Saito T, Saido TC, Funane T. Early Identification of Alzheimer's Disease in Mouse Models: Application of Deep Neural Network Algorithm to Cognitive Behavioral Parameters. iScience 2021; 24:102198. [PMID: 33733064 PMCID: PMC7937558 DOI: 10.1016/j.isci.2021.102198] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/21/2020] [Revised: 01/12/2021] [Accepted: 02/11/2021] [Indexed: 01/15/2023] Open
Abstract
Alzheimer's disease (AD) is a worldwide burden. Diagnosis is complicated by the fact that AD is asymptomatic at an early stage. Studies using AD-modeled animals offer important and useful insights. Here, we classified mice with a high risk of AD at a preclinical stage by using only their behaviors. Wild-type and knock-in AD-modeled (App NL-G-F/NL-G-F ) mice were raised, and their cognitive behaviors were assessed in an automated monitoring system. The classification utilized a machine learning method, i.e., a deep neural network, together with optimized stepwise feature selection and cross-validation. The AD risk could be identified on the basis of compulsive and learning behaviors (89.3% ± 9.8% accuracy) shown by AD-modeled mice in the early age (i.e., 8-12 months old) when the AD symptomatic cognitions were relatively underdeveloped. This finding reveals the advantage of machine learning in unveiling the importance of compulsive and learning behaviors for early AD diagnosis in mice.
Collapse
Affiliation(s)
- Stephanie Sutoko
- Hitachi, Ltd, Research and Development Group, Center for Exploratory Research, Kokubunji, Tokyo 185-8601, Japan
| | - Akira Masuda
- Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
- Organization for Research Initiatives and Development, Doshisha University, Kyotanabe, Kyoto 610-0394, Japan
| | - Akihiko Kandori
- Hitachi, Ltd, Research and Development Group, Center for Exploratory Research, Kokubunji, Tokyo 185-8601, Japan
| | - Hiroki Sasaguri
- Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
| | - Takashi Saito
- Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
- Department of Neurocognitive Science, Institute of Brain Science, Nagoya City University Graduate School of Medical Sciences, Nagoya, Aichi 467-8601, Japan
| | - Takaomi C. Saido
- Laboratory for Proteolytic Neuroscience, RIKEN Center for Brain Science, Wako, Saitama 351-0198, Japan
| | - Tsukasa Funane
- Hitachi, Ltd, Research and Development Group, Center for Exploratory Research, Kokubunji, Tokyo 185-8601, Japan
| |
Collapse
|
6
|
van Havre Z, Maruff P, Villemagne VL, Mengersen K, Rousseau J, White N, Doecke JD. Identification of Pre-Clinical Alzheimer's Disease in a Population of Elderly Cognitively Normal Participants. J Alzheimers Dis 2020; 73:683-693. [PMID: 31868673 DOI: 10.3233/jad-191095] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Alzheimer's disease (AD) has a long pathological process, with an approximate lead-time of 20 years. During the early stages of the disease process, little evidence of the building pathology is identifiable without cerebrospinal fluid and/or imaging analyses. Clinical manifestations of AD do not present until irreversible pathological changes have occurred. Given an opportunity to provide treatment prior to irreversible pathological change, this study aims to identify a subgroup of cognitively normal (CN) participants from the Australian Imaging, Biomarker & Lifestyle Flagship Study of Ageing (AIBL), where subtle changes in cognition are indicative of early AD-related pathology. Using a Bayesian method for unsupervised clustering via mixture models, we define an aggregate measure of posterior probabilities (AMPP score) establishing the likelihood of pre-clinical AD. From Baseline through to 54 months, visuo-spatial function had the greatest contribution to the AMPP score, followed by attention and processing speed and visual memory. Participants with the highest AMPP scores had both increasing neo-cortical amyloid burden and decreasing hippocampus volume over 54 months, compared to those in the lowest category with stable amyloid burden and hippocampus volume. The identification of a possible pre-clinical stage in CN participants via this method, without the aid of disease specific biomarkers, represents an important step in utilizing the strength of cognitive composite scores for the early detection of AD pathology.
Collapse
Affiliation(s)
- Zoe van Havre
- ACEMS, Queensland University of Technology, Queensland, Australia.,CEREMADE, Universite Paris Dauphine, Paris, France
| | - Paul Maruff
- Mental Health Research Institute, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Victoria, Australia
| | - Victor L Villemagne
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Victoria, Australia.,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Victoria, Australia
| | - Kerrie Mengersen
- ACEMS, Queensland University of Technology, Queensland, Australia
| | | | - Nicole White
- ACEMS, Queensland University of Technology, Queensland, Australia
| | - James D Doecke
- CSIRO Health and Biosecurity/Australian e-Health Research Centre, Herston, Queensland, Australia
| |
Collapse
|
7
|
Sun Z, Wang Z, Xu L, Lv X, Li Q, Wang H, Yu X. Characteristics of Cognitive Deficit in Amnestic Mild Cognitive Impairment With Subthreshold Depression. J Geriatr Psychiatry Neurol 2019; 32:344-353. [PMID: 31480987 DOI: 10.1177/0891988719865943] [Citation(s) in RCA: 13] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/11/2022]
Abstract
It is widely recognized that depression may precipitate the incidence of dementia in the elderly individuals and individuals with amnestic mild cognitive impairment (aMCI) in particular. However, the association between subthreshold depression (SD) and cognitive deficits in patients with aMCI remains unclear. To address this, we collected demographic information and conducted a battery of neuropsychological cognitive assessments in 33 aMCI participants with SD (aMCI/SD+), 33 nondepressed aMCI participants (aMCI/SD-), and 53 normal controls (NC). Both aMCI groups showed significantly poorer performance in most cognitive domains relative to the NC group (ie, memory, language, processing speed, and executive function). Notably, the aMCI/SD+ group showed significantly poorer attention/working memory compared with the aMCI/SD- group. Multiple linear regression analyses revealed a significant negative association between the severity of depressive symptoms and attention/working memory capacity (β = - .024, P = .024), accounting for 8.28% of the variations in this cognitive domain. All statistical analyses were adjusted by age, sex, and years of education. A logistic regression model had an accuracy of 72.4% in discriminating between the aMCI/SD+ and aMCI/SD- groups based on individual cognitive profiles over 6 domains. Our findings indicate that patients with aMCI with and without SD have distinct patterns of cognitive impairment. This finding may facilitate the diagnosis and treatment of SD in patients with aMCI.
Collapse
Affiliation(s)
- Zhiyu Sun
- 1 School of Mental Health, Wenzhou Medical University, Wenzhou, China.,2 Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.,3 National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China.,4 Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Beijing, China
| | - Zhijiang Wang
- 2 Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.,3 National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China.,4 Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Beijing, China.,5 Center for Advanced Medical Imaging Sciences, NMMI, Radiology, Massachusetts General Hospital, Boston, MA, USA
| | - Lujie Xu
- 1 School of Mental Health, Wenzhou Medical University, Wenzhou, China.,2 Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.,3 National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China.,4 Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Beijing, China
| | - Xiaozhen Lv
- 2 Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.,3 National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China.,4 Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Beijing, China
| | - Quanzheng Li
- 5 Center for Advanced Medical Imaging Sciences, NMMI, Radiology, Massachusetts General Hospital, Boston, MA, USA
| | - Huali Wang
- 2 Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.,3 National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China.,4 Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Beijing, China
| | - Xin Yu
- 1 School of Mental Health, Wenzhou Medical University, Wenzhou, China.,2 Peking University Institute of Mental Health (Sixth Hospital), Beijing, China.,3 National Clinical Research Center for Mental Disorders & Key Laboratory of Mental Health, Ministry of Health, Peking University, Beijing, China.,4 Beijing Municipal Key Laboratory for Translational Research on Diagnosis and Treatment of Dementia, Beijing, China
| |
Collapse
|
8
|
Carr SJ, Jaeger J, Bian S, He P, Maserejian N, Wang W, Maruff P, Enayetallah A, Wang Y, Chen Z, Lerner A, Tatsuoka C. Associating Cognition With Amyloid Status Using Partially Ordered Set Analysis. Front Neurol 2019; 10:976. [PMID: 31572291 PMCID: PMC6753225 DOI: 10.3389/fneur.2019.00976] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/10/2019] [Accepted: 08/27/2019] [Indexed: 11/13/2022] Open
Abstract
Background: The presence of brain amyloid-beta positivity is associated with cognitive impairment and dementia, but whether there are specific aspects of cognition that are most linked to amyloid-beta is unclear. Analysis of neuropsychological test data presents challenges since a single test often requires drawing upon multiple cognitive functions to perform well. It can thus be imprecise to link performance on a given test to a specific cognitive function. Our objective was to provide insight into how cognitive functions are associated with brain amyloid-beta positivity among samples consisting of cognitively normal and mild cognitively impaired (MCI) subjects, by using partially ordered set models (POSETs). Methods: We used POSET classification models of neuropsychological test data to classify samples to detailed cognitive profiles using ADNI2 and AIBL data. We considered 3 gradations of episodic memory, cognitive flexibility, verbal fluency, attention and perceptual motor speed, and performed group comparisons of cognitive functioning stratified by amyloid positivity (yes/no) and age (<70, 70-80, 81-90 years). We also employed random forest methods stratified by age to assess the effectiveness of cognitive testing in predicting amyloid positivity, in addition to demographic variables, and APOE4 allele count. Results: In ADNI2, differences in episodic memory and attention by amyloid were found for <70, and 70-80 years groups. In AIBL, episodic memory differences were found in the 70-80 years age group. In both studies, no cognitive differences were found in the 81-90 years group. The random forest analysis indicates that variable importance in classification depends on age. Cognitive testing that targets an intermediate level of episodic memory and delayed recall, in addition to APOE4 allele count, are the most important variables in both studies. Conclusions: In the ADNI2 and AIBL samples, the associations between specific cognitive abilities and brain amyloid-beta positivity depended on age, but in general episodic memory was most consistently predictive of brain amyloid-beta positivity. Random forest methods and OOB error rates establish the feasibility of predicting the presence of brain beta-amyloid using cognitive testing, APOE4 genotyping and demographic variables.
Collapse
Affiliation(s)
- Sarah J.A. Carr
- Department of Neurology, Case Western Reserve University, Cleveland, OH, United States
- Neuroimaging Department, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, United Kingdom
| | - Judith Jaeger
- CognitionMetrics, LLC, Wilmington, DE, United States
- Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine, Bronx, NY, United States
| | | | - Ping He
- Biogen, Cambridge, MA, United States
| | | | | | - Paul Maruff
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
- CogState Ltd., Melbourne, VIC, Australia
| | | | - Yanming Wang
- Department of Radiology, Case Western Reserve University, Cleveland, OH, United States
| | - Zhengyi Chen
- Department of Neurology, Case Western Reserve University, Cleveland, OH, United States
| | - Alan Lerner
- Department of Neurology, Case Western Reserve University, Cleveland, OH, United States
- Neurological Institute, University Hospitals Cleveland Medical Center, Beachwood, OH, United States
| | - Curtis Tatsuoka
- Department of Neurology, Case Western Reserve University, Cleveland, OH, United States
- Neurological Institute, University Hospitals Cleveland Medical Center, Beachwood, OH, United States
- Department of Population and Quantitative Health Sciences, Case Western Reserve University, Cleveland, OH, United States
| | | |
Collapse
|
9
|
The effect of preclinical Alzheimer's disease on age-related changes in intelligence in cognitively normal older adults. INTELLIGENCE 2018. [DOI: 10.1016/j.intell.2018.07.004] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
10
|
Gardener SL, Rainey-Smith SR, Sohrabi HR, Weinborn M, Verdile G, Fernando WMADB, Lim YY, Harrington K, Burnham S, Taddei K, Masters CL, Macaulay SL, Rowe CC, Ames D, Maruff P, Martins RN. Increased Carbohydrate Intake is Associated with Poorer Performance in Verbal Memory and Attention in an APOE Genotype-Dependent Manner. J Alzheimers Dis 2018; 58:193-201. [PMID: 28387666 DOI: 10.3233/jad-161158] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/07/2023]
Abstract
Evidence suggests that a diet low in carbohydrates can impact on cognitive performance among those with Alzheimer's disease (AD). However, there is a lack of data assessing this relationship among cognitively normal (CN) older adults at increased future risk of developing AD due to carriage of the apolipoprotein E (APOE) ɛ4 allele. We assessed the cross-sectional association between carbohydrate intake, cognitive performance, and cerebral amyloid-β (Aβ) load in CN older adults, genotyped for APOEɛ4 allele carrier status. Greater carbohydrate intake was associated with poorer performance in verbal memory in APOEɛ4 allele non-carriers, and poorer performance in attention in APOEɛ4 allele carriers. There were no associations between carbohydrate intake and cerebral Aβ load. These results provide support to the idea that decreasing carbohydrate intake may offer neurocognitive benefits, with specific cognitive domains affected in an APOE genotype-dependent manner. These findings warrant further investigation utilizing a longitudinal study design.
Collapse
Affiliation(s)
- Samantha L Gardener
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | - Stephanie R Rainey-Smith
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | - Hamid R Sohrabi
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.,Department of Biomedical Sciences, Macquarie University, NSW, Australia
| | - Michael Weinborn
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.,School of Psychology, University of Western Australia, Crawley, WA, Australia
| | - Giuseppe Verdile
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.,School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University of Technology, Bentley, WA, Australia
| | - W M A D Binosha Fernando
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | - Yen Ying Lim
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | - Karra Harrington
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia.,Cooperative Research Centre (CRC) for Mental Health, Carlton South, VIC, Australia
| | - Samantha Burnham
- CSIRO Computational Informatics, Preventative Health Flagship, Floreat, WA, Australia
| | - Kevin Taddei
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC, Australia
| | | | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Centre for PET, Austin Health, Heidelberg, VIC, Australia
| | - David Ames
- National Ageing Research Institute, Royal Melbourne Hospital, Melbourne, Australia.,Academic Unit for Psychiatry of Old Age, University of Melbourne, Melbourne, Australia
| | | | - Ralph N Martins
- Centre of Excellence for Alzheimer's disease Research & Care, School of Medical and Health Sciences, Edith Cowan University, Joondalup, WA, Australia.,Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia.,Department of Biomedical Sciences, Macquarie University, NSW, Australia
| | | |
Collapse
|
11
|
Cortical β-amyloid burden, gray matter, and memory in adults at varying APOE ε4 risk for Alzheimer's disease. Neurobiol Aging 2017; 61:207-214. [PMID: 29111487 DOI: 10.1016/j.neurobiolaging.2017.09.027] [Citation(s) in RCA: 24] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/26/2017] [Revised: 09/03/2017] [Accepted: 09/26/2017] [Indexed: 01/16/2023]
Abstract
Models of preclinical Alzheimer's disease (AD) propose that cerebral amyloidosis leads to neurodegeneration and subsequent cognitive decline. This study investigated whether APOE genotype is related to β-amyloid (Aβ) burden in brain regions preferentially affected by AD and whether Aβ burden is associated with gray-matter (GM) fraction (as a marker of neurodegeneration) and episodic memory performance in cognitively normal middle-aged individuals at varying genetic risk for AD. Three groups of cognitively normal participants aged 50-65 years with a first-degree family history of AD (APOE genotype ε4ε4 [n = 15], ε3ε4 [n = 15], and ε3ε3 [n = 15]) underwent [11C]PiB positron emission tomography scans to quantify cortical Aβ, brain magnetic resonance imaging, and neuropsychological testing. APOE ε4ε4 participants demonstrated significantly higher cortical Aβ burden than APOE ε3ε3 (p < 0.001). Furthermore, cortical Aβ burden was inversely associated with cortical GM fraction (p = 0.017) but not episodic memory performance. In cognitively normal, middle-aged individuals, Aβ burden is significantly associated with GM fraction but not episodic memory performance. These findings are consistent with models of preclinical AD in which neurodegeneration occurs before manifest cognitive decline.
Collapse
|
12
|
Harrington KD, Lim YY, Ames D, Hassenstab J, Laws SM, Martins RN, Rainey-Smith S, Robertson J, Rowe CC, Salvado O, Doré V, Villemagne VL, Snyder PJ, Masters CL, Maruff P. Amyloid β-associated cognitive decline in the absence of clinical disease progression and systemic illness. ALZHEIMER'S & DEMENTIA: DIAGNOSIS, ASSESSMENT & DISEASE MONITORING 2017; 8:156-164. [PMID: 28761926 PMCID: PMC5520957 DOI: 10.1016/j.dadm.2017.05.006] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Indexed: 01/08/2023]
Abstract
Introduction High levels of amyloid β (Aβ) are associated with cognitive decline in cognitively normal (CN) older adults. This study investigated the nature of cognitive decline in healthy individuals who did not progress to mild cognitive impairment or dementia. Method Cognition was measured over 72 months and compared between low (Aβ−) and high (Aβ+) CN older adults (n = 335) who did not progress to mild cognitive impairment or dementia and who remained free of severe or uncontrolled systemic illness. Results Compared to the Aβ− group, the Aβ+ group showed no cognitive impairment at baseline but showed substantial decline in verbal learning, episodic memory, and attention over 72 months. Discussion Moderate cognitive decline, particularly for learning and memory, was associated with Aβ+ in CN older adults in the absence of clinical disease progression and uncontrolled or serious comorbid illness.
Collapse
Affiliation(s)
- Karra D Harrington
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia
| | - Yen Ying Lim
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Melbourne, Victoria, Australia
| | - David Ames
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, The University of Melbourne, Parkville, Victoria, Australia.,National Ageing Research Institute, Parkville, Victoria, Australia
| | - Jason Hassenstab
- Charles F. and Joanne Knight Alzheimer's Disease Research Center, Washington University School of Medicine, St. Louis, MO, USA.,Department of Neurology, Washington University School of Medicine, St. Louis, MO, USA.,Department of Psychological & Brain Sciences, Washington University, St. Louis, MO, USA
| | - Simon M Laws
- Cooperative Research Centre for Mental Health, Parkville, Victoria, Australia.,Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,School of Biomedical Sciences, Faculty of Health Sciences, Curtin Health Innovation Research Institute, Curtin University, Western Australia, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia.,Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia, Australia
| | - Joanne Robertson
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Christopher C Rowe
- Department of Molecular Imaging, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Olivier Salvado
- CSIRO Health and Biosecurity, The Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Vincent Doré
- Department of Molecular Imaging, Austin Health, Melbourne, Victoria, Australia.,CSIRO Health and Biosecurity, The Australian eHealth Research Centre, Brisbane, Queensland, Australia
| | - Victor L Villemagne
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,Department of Molecular Imaging, Austin Health, Melbourne, Victoria, Australia.,Department of Medicine, Austin Health, The University of Melbourne, Melbourne, Victoria, Australia
| | - Peter J Snyder
- Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA.,Department of Neurology, Rhode Island Hospital, Alpert Medical School of Brown University, Providence, RI, USA
| | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, Parkville, Victoria, Australia.,CogState Ltd., Melbourne, Victoria, Australia
| |
Collapse
|
13
|
Pietrzak RH, Laws SM, Lim YY, Bender SJ, Porter T, Doecke J, Ames D, Fowler C, Masters CL, Milicic L, Rainey-Smith S, Villemagne VL, Rowe CC, Martins RN, Maruff P. Plasma Cortisol, Brain Amyloid-β, and Cognitive Decline in Preclinical Alzheimer's Disease: A 6-Year Prospective Cohort Study. BIOLOGICAL PSYCHIATRY: COGNITIVE NEUROSCIENCE AND NEUROIMAGING 2016; 2:45-52. [PMID: 29560886 DOI: 10.1016/j.bpsc.2016.08.006] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/29/2016] [Revised: 08/17/2016] [Accepted: 08/29/2016] [Indexed: 12/22/2022]
Abstract
BACKGROUND Hypothalamic-pituitary-adrenal axis dysregulation, which is typically assessed by measuring cortisol levels, is associated with cognitive dysfunction, hippocampal atrophy, and increased risk for mild cognitive impairment and Alzheimer's disease (AD). However, little is known about the role of hypothalamic-pituitary-adrenal axis dysregulation in moderating the effect of high levels of amyloid-β (Aβ+) on cognitive decline in the preclinical phase of AD, which is often protracted, and thus offers opportunities for prevention and early intervention. METHODS Using data from a 6-year multicenter prospective cohort study, we evaluated the relation between Aβ level, plasma cortisol level, and cognitive decline in 416 cognitively normal older adults. RESULTS Results revealed that Aβ+ older adults experienced faster decline than Aβ- older adults in all cognitive domains (Cohen's d at 6-year assessment = 0.37-0.65). They further indicated a significant interaction between Aβ and cortisol levels for global cognition (d = 0.32), episodic memory (d = 0.50), and executive function (d = 0.59) scores, with Aβ+ older adults with high cortisol levels having significantly faster decline in these domains compared with Aβ+ older adults with low cortisol levels. These effects were independent of age, sex, APOE genotype, anxiety symptoms, and radiotracer type. CONCLUSIONS In cognitively healthy older adults, Aβ+ is associated with greater cognitive decline and high plasma cortisol levels may accelerate the effect of Aβ+ on decline in global cognition, episodic memory, and executive function. These results suggest that therapies targeted toward lowering plasma cortisol and Aβ levels may be helpful in mitigating cognitive decline in the preclinical phase of AD.
Collapse
Affiliation(s)
- Robert H Pietrzak
- U.S. Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven; Department of Psychiatry, Yale University School of Medicine, New Haven, Connecticut.
| | - Simon M Laws
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia; Co-operative Research Centre for Mental Health
| | - Yen Ying Lim
- The Florey Institute, The University of Melbourne, Parkville, Victoria
| | - Sophie J Bender
- School of Health Sciences, University of Notre Dame Australia, Fremantle, Western Australia
| | - Tenielle Porter
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia; Co-operative Research Centre for Mental Health
| | - James Doecke
- The Commonwealth Scientific and Industrial Research Organization, Canberra
| | - David Ames
- Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew; National Ageing Research Institute, Parkville, Victoria
| | | | - Colin L Masters
- The Florey Institute, The University of Melbourne, Parkville, Victoria
| | - Lidija Milicic
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia
| | - Victor L Villemagne
- The Florey Institute, The University of Melbourne, Parkville, Victoria; Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia; Department of Nuclear Medicine and Centre for PET, Austin Health
| | - Christopher C Rowe
- Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia; Department of Nuclear Medicine and Centre for PET, Austin Health
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, Western Australia; Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, Western Australia
| | - Paul Maruff
- The Florey Institute, The University of Melbourne, Parkville, Victoria; Department of Medicine, Austin Health, The University of Melbourne, Heidelberg; Cogstate Ltd., Melbourne, Victoria, Australia
| | | |
Collapse
|
14
|
Burnham SC, Rowe CC, Baker D, Bush AI, Doecke JD, Faux NG, Laws SM, Martins RN, Maruff P, Macaulay SL, Rainey-Smith S, Savage G, Ames D, Masters CL, Wilson W, Villemagne VL. Predicting Alzheimer disease from a blood-based biomarker profile: A 54-month follow-up. Neurology 2016; 87:1093-101. [PMID: 27534714 DOI: 10.1212/wnl.0000000000003094] [Citation(s) in RCA: 25] [Impact Index Per Article: 3.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/17/2016] [Accepted: 06/01/2016] [Indexed: 11/15/2022] Open
Abstract
OBJECTIVE We assessed a blood-based signature, which previously demonstrated high accuracy at stratifying individuals with high or low neocortical β-amyloid burden (NAB), to determine whether it could also identify individuals at risk of progression to Alzheimer disease (AD) within 54 months. METHODS We generated the blood-based signature for 585 healthy controls (HCs) and 74 participants with mild cognitive impairment (MCI) from the Australian Imaging, Biomarkers and Lifestyle Study who underwent clinical reclassification (blinded to biomarker findings) at 54-month follow-up. The individuals were split into estimated high and low NAB groups based on a cutoff of 1.5 standardized uptake value ratio. We assessed the predictive accuracy of the high and low NAB groupings based on progression to mild cognitive impairment or AD according to clinical reclassification at 54-month follow-up. RESULTS Twelve percent of HCs with estimated high NAB progressed in comparison to 5% of HCs with estimated low NAB (odds ratio = 2.4). Forty percent of the participants with MCI who had estimated high NAB progressed in comparison to 5% of the participants with MCI who had estimated low NAB (odds ratio = 12.3). These ratios are in line with those reported for Pittsburgh compound B-PET results. Individuals with estimated high NAB had faster rates of memory decline than those with estimated low NAB. CONCLUSION These findings suggest that a simple blood-based signature not only provides estimates of NAB but also predicts cognitive decline and disease progression, identifying individuals at risk of progressing toward AD at the prodromal and preclinical stages.
Collapse
Affiliation(s)
- Samantha C Burnham
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia.
| | - Christopher C Rowe
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - David Baker
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Ashley I Bush
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - James D Doecke
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Noel G Faux
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Simon M Laws
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Ralph N Martins
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Paul Maruff
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - S Lance Macaulay
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Stephanie Rainey-Smith
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Greg Savage
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - David Ames
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Colin L Masters
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - William Wilson
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| | - Victor L Villemagne
- From eHealth (S.C.B.), CSIRO Health and Biosecurity, Floreat; Department of Nuclear Medicine and Centre for PET (C.C.R.), Austin Health, Heidelberg; Department of Medicine (C.C.R., V.L.V.), Austin Health, University of Melbourne, Heidelberg, Australia; Janssen Research and Development (D.B.), Titusville, NJ; Mental Health Research Institute (A.I.B., N.G.F.), Academic Unit for Psychiatry of Old Age, Department of Psychiatry (D.A.), and The Florey Institute (C.L.M., V.L.V.), University of Melbourne, Parkville; eHealth (J.D.D.), CSIRO Health and Biosecurity, Herston; Centre of Excellence for Alzheimer's Disease Research & Care (S.M.L., R.N.M., S.R.-S.), School of Medical Sciences, Edith Cowan University, Joondalup; School of Biomedical Sciences (S.M.L.), Faculty of Health Sciences, Curtin University, Bentley; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital) (R.N.M., S.R.-S.), Perth; Cogstate (P.M.), Melbourne; CSIRO Food and Nutrition Flagship (S.L.M.), Melbourne; Department of Psychology (G.S.), Macquarie University, Sydney; and eHealth (W.W.), CSIRO Health and Biosecurity, North Ryde, Australia
| |
Collapse
|
15
|
Lim YY, Laws SM, Villemagne VL, Pietrzak RH, Porter T, Ames D, Fowler C, Rainey-Smith S, Snyder PJ, Martins RN, Salvado O, Bourgeat P, Rowe CC, Masters CL, Maruff P. Aβ-related memory decline inAPOEε4 noncarriers. Neurology 2016; 86:1635-42. [DOI: 10.1212/wnl.0000000000002604] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2015] [Accepted: 01/19/2016] [Indexed: 11/15/2022] Open
|
16
|
Buckley RF, Maruff P, Ames D, Bourgeat P, Martins RN, Masters CL, Rainey-Smith S, Lautenschlager N, Rowe CC, Savage G, Villemagne VL, Ellis KA. Subjective memory decline predicts greater rates of clinical progression in preclinical Alzheimer's disease. Alzheimers Dement 2016; 12:796-804. [PMID: 26852195 DOI: 10.1016/j.jalz.2015.12.013] [Citation(s) in RCA: 117] [Impact Index Per Article: 14.6] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/11/2015] [Revised: 10/27/2015] [Accepted: 12/15/2015] [Indexed: 01/31/2023]
Abstract
INTRODUCTION The objective of this study was to determine the utility of subjective memory decline (SMD) to predict episodic memory change and rates of clinical progression in cognitively normal older adults with evidence of high β-amyloid burden (CN Aβ+). METHODS Fifty-eight CN Aβ+ participants from the Australian Imaging, Biomarkers, and Lifestyle study responded to an SMD questionnaire and underwent comprehensive neuropsychological assessments. Participant data for three follow-up assessments were analyzed. RESULTS In CN Aβ+, subjects with high SMD did not exhibit significantly greater episodic memory decline than those with low SMD. High SMD was related to greater rates of progression to mild cognitive impairment or Alzheimer's disease (AD) dementia (hazard ratio = 5.1; 95% confidence interval, 1.4-20.0, P = .02) compared with low SMD. High SMD was associated with greater depressive symptomatology and smaller left hippocampal volume. DISCUSSION High SMD is a harbinger of greater rates of clinical progression in preclinical AD. Although SMD reflects broader diagnostic implications for CN Aβ+, more sensitive measures may be required to detect early subtle cognitive change.
Collapse
Affiliation(s)
- Rachel F Buckley
- Melbourne School of Psychological Sciences, University of Melbourne, Melbourne, Australia.
| | | | - David Ames
- The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne
| | - Pierrick Bourgeat
- The Australian eHealth Research Centre, CSIRO Health & Biosecurity Flagship, QLD, Australia
| | - Ralph N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, WA, Australia; School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing, University of Western Australia; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | - Colin L Masters
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia
| | - Stephanie Rainey-Smith
- Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences, Edith Cowan University, WA, Australia; Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | - Nicola Lautenschlager
- The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne; School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing, University of Western Australia
| | - Christopher C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia; Department of Medicine, Austin Health, University of Melbourne, Melbourne, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders, Macquarie University, Sydney, Australia
| | - Victor L Villemagne
- The Florey Institute of Neuroscience and Mental Health, University of Melbourne, Melbourne, Australia; Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, Australia; Department of Medicine, Austin Health, University of Melbourne, Melbourne, Australia
| | - Kathryn A Ellis
- The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry, University of Melbourne
| |
Collapse
|
17
|
Lim YY, Villemagne VL, Laws SM, Pietrzak RH, Snyder PJ, Ames D, Ellis KA, Harrington K, Rembach A, Martins RN, Rowe CC, Masters CL, Maruff P. APOE and BDNF polymorphisms moderate amyloid β-related cognitive decline in preclinical Alzheimer's disease. Mol Psychiatry 2015; 20:1322-8. [PMID: 25288138 PMCID: PMC4759101 DOI: 10.1038/mp.2014.123] [Citation(s) in RCA: 99] [Impact Index Per Article: 11.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/19/2014] [Revised: 07/29/2014] [Accepted: 08/21/2014] [Indexed: 12/11/2022]
Abstract
Accumulation of β-amyloid (Aβ) in the brain is associated with memory decline in healthy individuals as a prelude to Alzheimer's disease (AD). Genetic factors may moderate this decline. We examined the role of apolipoprotein E (ɛ4 carrier[ɛ4(+)], ɛ4 non-carrier[ɛ4(-)]) and brain-derived neurotrophic factor (BDNF(Val/Val), BDNF(Met)) in the extent to which they moderate Aβ-related memory decline. Healthy adults (n=333, Mage=70 years) enrolled in the Australian Imaging, Biomarkers and Lifestyle study underwent Aβ neuroimaging. Neuropsychological assessments were conducted at baseline, 18-, 36- and 54-month follow-ups. Aβ positron emission tomography neuroimaging was used to classify participants as Aβ(-) or Aβ(+). Relative to Aβ(-)ɛ4(-), Aβ(+)ɛ4(+) individuals showed significantly faster rates of cognitive decline over 54 months across all domains (d=0.40-1.22), while Aβ(+)ɛ4(-) individuals showed significantly faster decline only on verbal episodic memory (EM). There were no differences in rates of cognitive change between Aβ(-)ɛ4(-) and Aβ(-)ɛ4(+) groups. Among Aβ(+) individuals, ɛ4(+)/BDNF(Met) participants showed a significantly faster rate of decline on verbal and visual EM, and language over 54 months compared with ɛ4(-)/BDNF(Val/Val) participants (d=0.90-1.02). At least two genetic loci affect the rate of Aβ-related cognitive decline. Aβ(+)ɛ4(+)/BDNF(Met) individuals can expect to show clinically significant memory impairment after 3 years, whereas Aβ(+)ɛ4(+)/BDNF(Val/Val) individuals can expect a similar degree of impairment after 10 years. Little decline over 54 months was observed in the Aβ(-) and Aβ(+) ɛ4(-) groups, irrespective of BDNF status. These data raise important prognostic issues in managing preclinical AD, and should be considered in designing secondary preventative clinical trials.
Collapse
Affiliation(s)
- Y Y Lim
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia,Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA,Department of Neurology, Rhode Island Hospital, Providence, RI, USA
| | - V L Villemagne
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia,Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia,Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia
| | - S M Laws
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, WA, Australia,Sir James McCusker Alzheimer's Disease Research Unit, Hollywood Private Hospital, Perth, WA, Australia,Co-operative Research Centre for Mental Health
| | - R H Pietrzak
- Department of Psychiatry, Yale University School of Medicine, New Haven, CT, USA
| | - P J Snyder
- Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA,Department of Neurology, Rhode Island Hospital, Providence, RI, USA
| | - D Ames
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, St. Vincent's Health, University of Melbourne, Kew, VIC, Australia,National Ageing Research Institute, Parkville, VIC, Australia
| | - K A Ellis
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia,National Ageing Research Institute, Parkville, VIC, Australia
| | - K Harrington
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
| | - A Rembach
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia
| | - R N Martins
- Centre of Excellence for Alzheimer's Disease Research and Care, Edith Cowan University, Joondalup, WA, Australia
| | - C C Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia,Department of Medicine, Austin Health, University of Melbourne, Heidelberg, VIC, Australia
| | - C L Masters
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia,Florey Institute of Neuroscience and Mental Health, University of Melbourne, Kenneth Myer Building, Genetics Lane, Royal Parade, Melbourne, VIC 3000, Australia. E-mail:
| | - P Maruff
- Florey Institute of Neuroscience and Mental Health, University of Melbourne, Parkville, VIC, Australia,CogState Ltd, Melbourne, VIC, Australia
| |
Collapse
|
18
|
Pietrzak RH, Scott JC, Neumeister A, Lim YY, Ames D, Ellis KA, Harrington K, Lautenschlager NT, Szoeke C, Martins RN, Masters CL, Villemagne VL, Rowe CC, Maruff P. Anxiety symptoms, cerebral amyloid burden and memory decline in healthy older adults without dementia: 3-year prospective cohort study. Br J Psychiatry 2015; 204:400-1. [PMID: 24526746 DOI: 10.1192/bjp.bp.113.134239] [Citation(s) in RCA: 29] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Although beta-amyloid, anxiety and depression have linked cross-sectionally to reduced memory function in healthy older adults without dementia, prospective data evaluating these associations are lacking. Using data an observational cohort study of 178 healthy older adults without dementia followed for 3 years, we found that anxiety symptoms significantly moderated the relationship between beta-amyloid level and decline in verbal (Cohen's d = 0.65) and episodic (Cohen's d = 0.38) memory. Anxiety symptoms were additionally linked to greater decline in executive function, irrespective of beta-amyloid and other risk factors. These findings suggest that interventions to mitigate anxiety symptoms may help delay memory decline in otherwise healthy older adults with elevated beta-amyloid.
Collapse
Affiliation(s)
- Robert H Pietrzak
- Robert H. Pietrzak, PhD, MPH, J. Cobb Scott, PhD, United States Department of Veterans Affairs National Center for Posttraumatic Stress Disorder, Clinical Neurosciences Division, VA Connecticut Healthcare System, West Haven and Department of Psychiatry, Yale School of Medicine, New Haven, Connecticut, USA; Alexander Neumeister, MD, Departments of Psychiatry and Radiology, New York University School of Medicine, New York, USA; Yen Ying Lim, PhD, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; David Ames, MD, Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew and National Ageing Research Institute, Parkville, Victoria, Australia; Kathryn A. Ellis, PhD, The Florey Institute of Neuroscience and Mental Health, Parkville, Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew and National Ageing Research Institute, Parkville, Victoria, Australia; Karra Harrington, BA, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; Nicola T. Lautenschlager, MD, Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry, The University of Melbourne, Kew, Victoria and School of Psychiatry and Clinical Neurosciences and WA Centre for Health & Ageing, The University of Western Australia, Perth, Australia; Cassandra Szoeke, MD, National Ageing Research Institute, Parkville, Mental Health Research Institute, The University of Melbourne, Parkville and CSIRO Preventative Health Flagship, Parkville, Victoria, Australia; Ralph N. Martins, PhD, Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences, Edith Cowan University, Perth, Western Australia, Australia; Colin L. Masters, MD, The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, Australia; Victor L. Villemagne, MD, The Flor
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
19
|
Dietary patterns and cognitive decline in an Australian study of ageing. Mol Psychiatry 2015; 20:860-6. [PMID: 25070537 DOI: 10.1038/mp.2014.79] [Citation(s) in RCA: 90] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/31/2013] [Revised: 06/17/2014] [Accepted: 06/18/2014] [Indexed: 01/03/2023]
Abstract
The aim of this paper was to investigate the association of three well-recognised dietary patterns with cognitive change over a 3-year period. Five hundred and twenty-seven healthy participants from the Australian Imaging, Biomarkers and Lifestyle study of ageing completed the Cancer Council of Victoria food frequency questionnaire at baseline and underwent a comprehensive neuropsychological assessment at baseline, 18 and 36 months follow-up. Individual neuropsychological test scores were used to construct composite scores for six cognitive domains and a global cognitive score. Based on self-reported consumption, scores for three dietary patterns, (1) Australian-style Mediterranean diet (AusMeDi), (2) western diet and (3) prudent diet were generated for each individual. Linear mixed model analyses were conducted to examine the relationship between diet scores and cognitive change in each cognitive domain and for the global score. Higher baseline adherence to the AusMeDi was associated with better performance in the executive function cognitive domain after 36 months in apolipoprotein E (APOE) ɛ4 allele carriers (P<0.01). Higher baseline western diet adherence was associated with greater cognitive decline after 36 months in the visuospatial cognitive domain in APOE ɛ4 allele non-carriers (P<0.01). All other results were not significant. Our findings in this well-characterised Australian cohort indicate that adherence to a healthy diet is important to reduce risk for cognitive decline, with the converse being true for the western diet. Executive function and visuospatial functioning appear to be particularly susceptible to the influence of diet.
Collapse
|
20
|
Burnham SC, Raghavan N, Wilson W, Baker D, Ropacki MT, Novak G, Ames D, Ellis K, Martins RN, Maruff P, Masters CL, Romano G, Rowe CC, Savage G, Macaulay SL, Narayan VA. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer’s Disease Trials: An AIBL Study. J Alzheimers Dis 2015; 46:1079-89. [DOI: 10.3233/jad-143015] [Citation(s) in RCA: 23] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
| | | | - William Wilson
- CSIRO Digital Productivity Flagship, North Ryde, NSW, Australia
| | - David Baker
- Janssen Research and Development, Titusville, NJ, USA
| | | | - Gerald Novak
- Janssen Research and Development, Raritan, NJ, USA
| | - David Ames
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
- National Ageing Research Institute, Parkville, VIC, Australia
| | - Kathryn Ellis
- Academic Unit for Psychiatry of Old Age, Department of Psychiatry, University of Melbourne, Parkville, VIC, Australia
| | - Ralph N. Martins
- Centre of Excellence for Alzheimer’s Disease Research & Care, School of Medical Sciences, Edith Cowan University, Joondalup, WA, Australia
- Sir James McCusker Alzheimer’s Disease Research Unit (Hollywood Private Hospital), Perth, WA, Australia
| | | | - Colin L. Masters
- Mental Health Research Institute (MHRI), The University of Melbourne, Parkville, VIC, Australia
| | - Gary Romano
- Janssen Research and Development, Raritan, NJ, USA
| | - Christopher C. Rowe
- Department of Nuclear Medicine and Centre for PET, Austin Health, Heidelberg, VIC, Australia
- Department of Medicine, Austin Health, The University of Melbourne, Heidelberg, VIC, Australia
| | - Greg Savage
- ARC Centre of Excellence in Cognition and its Disorders, and Department of Psychology, Macquarie University, Sydney, NSW, Australia
| | | | | | | | | |
Collapse
|
21
|
Trajectories of memory decline in preclinical Alzheimer's disease: results from the Australian Imaging, Biomarkers and Lifestyle Flagship Study of Ageing. Neurobiol Aging 2015; 36:1231-8. [DOI: 10.1016/j.neurobiolaging.2014.12.015] [Citation(s) in RCA: 65] [Impact Index Per Article: 7.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2014] [Revised: 12/10/2014] [Accepted: 12/13/2014] [Indexed: 11/18/2022]
|
22
|
Harrington KD, Lim YY, Gould E, Maruff P. Amyloid-beta and depression in healthy older adults: a systematic review. Aust N Z J Psychiatry 2015; 49:36-46. [PMID: 25414381 DOI: 10.1177/0004867414557161] [Citation(s) in RCA: 55] [Impact Index Per Article: 6.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 12/30/2022]
Abstract
OBJECTIVE Depression has been shown to be a risk factor for Alzheimer's disease (AD), and in older adults may provide a marker for the beginning of the prodromal phase of AD. The purpose of this systematic review is to examine the relationship between amyloid-β (Aβ), a key biomarker of AD, and depression in older adults. METHOD The literature search was limited to studies conducted from 2006 to 2014 that were published in English in peer-reviewed journals. Studies were selected if they included a group of older adults who either met established criteria for Major Depressive Disorder or Dysthymia; or were assessed for depressive symptoms on a standardised measure. Studies were also required to include an outcome variable that was a direct measure of Aβ levels in either blood or cerebrospinal fluid (CSF) samples, or via neuroimaging techniques such as positron emission tomography (PET). RESULTS Nineteen studies were identified, 15 of which found significant differences in Aβ levels between depressed and non-depressed older adults. However, studies were limited by their cross-sectional design, reliance on blood-based measures of Aβ, and potential sample bias. CONCLUSIONS Future investigations should consider prospective longitudinal design using neuroimaging and CSF measures of Aβ.
Collapse
Affiliation(s)
- Karra D Harrington
- School of Psychology, Deakin University, Geelong, Victoria, Australia Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia
| | - Yen Ying Lim
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia Department of Neurology, Warren Alpert School of Medicine, Brown University, Providence, RI, USA
| | - Emma Gould
- School of Psychology, Deakin University, Geelong, Victoria, Australia
| | - Paul Maruff
- Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, Victoria, Australia CogState Ltd., Melbourne, Victoria, Australia
| |
Collapse
|
23
|
Johnson P, Vandewater L, Wilson W, Maruff P, Savage G, Graham P, Macaulay LS, Ellis KA, Szoeke C, Martins RN, Rowe CC, Masters CL, Ames D, Zhang P. Genetic algorithm with logistic regression for prediction of progression to Alzheimer's disease. BMC Bioinformatics 2014; 15 Suppl 16:S11. [PMID: 25521394 PMCID: PMC4290638 DOI: 10.1186/1471-2105-15-s16-s11] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022] Open
Abstract
Background Assessment of risk and early diagnosis of Alzheimer's disease (AD) is a key to its prevention or slowing the progression of the disease. Previous research on risk factors for AD typically utilizes statistical comparison tests or stepwise selection with regression models. Outcomes of these methods tend to emphasize single risk factors rather than a combination of risk factors. However, a combination of factors, rather than any one alone, is likely to affect disease development. Genetic algorithms (GA) can be useful and efficient for searching a combination of variables for the best achievement (eg. accuracy of diagnosis), especially when the search space is large, complex or poorly understood, as in the case in prediction of AD development. Results Multiple sets of neuropsychological tests were identified by GA to best predict conversions between clinical categories, with a cross validated AUC (area under the ROC curve) of 0.90 for prediction of HC conversion to MCI/AD and 0.86 for MCI conversion to AD within 36 months. Conclusions This study showed the potential of GA application in the neural science area. It demonstrated that the combination of a small set of variables is superior in performance than the use of all the single significant variables in the model for prediction of progression of disease. Variables more frequently selected by GA might be more important as part of the algorithm for prediction of disease development.
Collapse
|